使用宽场荧光内镜检测近端结肠的无蒂锯齿状腺瘤
研究通过噬菌体展示技术鉴定出特异性结合无蒂锯齿状腺瘤(SSA)的肽KCCFPAQ,并在动物和临床安全研究中未观察到毒性。在临床成像研究中,该荧光标记肽使SSA区域平均荧光强度较正常结肠黏膜高2.43倍,区分SSA与正常黏膜的灵敏度为89%、特异度为92%。作者认为这种靶向成像方法或可用于常规结肠镜检查中对癌前锯齿状病变的早期检测。
要点
- 荧光标记肽KCCFPAQ可特异性结合SSA,表观解离常数Kd=72 nM。
- SSA区域平均荧光强度是正常结肠黏膜的2.43倍。
- 荧光标记区分SSA与正常结肠黏膜的灵敏度89%、特异度92%。
核心结论
- 鉴定出一种在动物和人体中未观察到毒性作用的荧光标记肽,可用于近端结肠病变的宽场成像。
- 该肽区分SSA与正常结肠黏膜的灵敏度为89%、特异度为92%。
- 作者认为这种靶向成像方法或可用于常规结肠镜检查中对癌前锯齿状病变的早期检测。
研究设计与样本
- 通过噬菌体展示技术,以含BRAF V600E突变的HT29结直肠癌细胞与Hs738.St/Int细胞进行消减杂交,鉴定特异性结合SSA的肽。
- 大鼠经结肠内给予0.0086 mg/kg、0.026 mg/kg或0.86 mg/kg肽或溶媒,每日两次监测发病率、死亡率和损伤以评估毒性。
- 临床安全研究:25例接受常规门诊结肠镜检查的受试者经喷雾导管局部给予荧光标记肽至近端结肠,其中3例给予2.25 μmol/L,22例给予76.4 μmol/L。
- 临床成像研究:38例接受常规门诊结肠镜检查、结直肠癌高风险或疑似未切除近端结肠息肉的受试者,先以白光内镜评估可疑区域,再局部给予76.4 μmol/L荧光标记肽至近端结肠,冲洗未结合肽后记录白光、反射和荧光视频。
- 内镜医师切除 identified 病变,由胃肠道病理学家进行组织学分析作为参考标准;另分析密歇根大学组织库标本中肽区分SSA与腺瘤、增生性息肉和正常结肠黏膜的能力。
主要发现
- 鉴定出肽序列KCCFPAQ,表观解离常数Kd=72 nM,表观结合时间常数K=0.174 min-1(5.76分钟)。
- 内镜荧光成像中,SSA区域平均荧光强度较正常结肠黏膜高2.43倍。
- 荧光标记区分SSA与正常结肠黏膜的灵敏度为89%,特异度为92%。
- 该肽在动物或患者中未观察到毒性作用。
- 离体标本分析中,肽结合SSA的平均荧光强度显著高于增生性息肉。
临床怎么用
- 作者认为这种靶向成像方法或可用于常规结肠镜检查中对癌前锯齿状病变的早期检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many cancers in the proximal colon develop via from sessile serrated adenomas (SSAs), which have flat, subtle features that are difficult to detect with conventional white-light colonoscopy. Many SSA cells have the V600E mutation in BRAF. We investigated whether this feature could be used with imaging methods to detect SSAs in patients. METHODS: We used phage display to identify a peptide that binds specifically to SSAs, using subtractive hybridization with HT29 colorectal cancer cells containing the V600E mutation in BRAF and Hs738.St/Int cells as a control. Binding of fluorescently labeled peptide to colorectal cancer cells was evaluated with confocal fluorescence microscopy. Rats received intra-colonic 0.0086 mg/kg, 0.026 mg/kg, or 0.86 mg/kg peptide or vehicle and morbidity, mortality, and injury were monitored twice daily to assess toxicity. In the clinical safety study, fluorescently labeled peptide was topically administered, using a spray catheter, to the proximal colon of 25 subjects undergoing routine outpatient colonoscopies (3 subjects were given 2.25 μmol/L and 22 patients were given 76.4 μmol/L). We performed blood cell count, chemistry, liver function, and urine analyses approximately 24 hours after peptide administration. In the clinical imaging study, 38 subjects undergoing routine outpatient colonoscopies, at high risk for colorectal cancer, or with a suspected unresected proximal colonic polyp, were first evaluated by white-light endoscopy to identify suspicious regions. The fluorescently labeled peptide (76.4 μmol/L) was administered topically to proximal colon, unbound peptide was washed away, and white-light, reflectance, and fluorescence videos were recorded digitally. Fluorescence intensities of SSAs were compared with those of normal colonic mucosa. Endoscopists resected identified lesions, which were analyzed histologically by gastrointestinal pathologists (reference standard). We also analyzed the ability of the peptide to identify SSAs vs adenomas, hyperplastic polyps, and normal colonic mucosa in specimens obtained from the tissue bank at the University of Michigan. RESULTS: We identified the peptide sequence KCCFPAQ and measured an apparent dissociation constant of Kd = 72 nM and an apparent association time constant of K = 0.174 min-1 (5.76 minutes). During fluorescence imaging of patients during endoscopy, regions of SSA had 2.43-fold higher mean fluorescence intensity than that for normal colonic mucosa. Fluorescence labeling distinguished SSAs from normal colonic mucosa with 89% sensitivity and 92% specificity. The peptide had no observed toxic effects in animals or patients. In the analysis of ex vivo specimens, peptide bound to SSAs had significantly higher mean fluorescence intensity than to hyperplastic polyps. CONCLUSIONS: We have identified a fluorescently labeled peptide that has no observed toxic effects in animals or humans and can be used for wide-field imaging of lesions in the proximal colon. It distinguishes SSAs from normal colonic mucosa with 89% sensitivity and 92% specificity. This targeted imaging method might be used in early detection of premalignant serrated lesions during routine colonoscopies. ClinicalTrials.gov ID: NCT02156557.
引用
- Joshi BP, Dai Z, Gao Z, et al. Detection of Sessile Serrated Adenomas in the Proximal Colon Using Wide-Field Fluorescence Endoscopy. Gastroenterology. 2016. PMID: 28012848. doi:10.1053/j.gastro.2016.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。